|
Liposome-encapsulated Daunorubicin-Cytarabine Clinical Trials
9 actively recruiting trials across 4 locations
Also known as: CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection +5 more
Pipeline
Phase 1: 2Phase 2: 4Phase 3: 1Phase 1/2: 2
Top Sponsors
- M.D. Anderson Cancer Center4
- National Cancer Institute (NCI)2
- Thomas Jefferson University1
- Ohio State University Comprehensive Cancer Center1
- Children's Oncology Group1
Indications
- Cancer9
- Refractory Acute Myeloid Leukemia5
- Recurrent Acute Myeloid Leukemia4
- Acute Myeloid Leukemia4
- Blasts More Than 5 Percent of Bone Marrow Nucleated Cells2
Houston, Texas4 trials
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M D Anderson Cancer Center
Phase 2
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M D Anderson Cancer Center
Phase 1
Birmingham, Alabama3 trials
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Hospital of Alabama
Phase 3
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
University of Alabama at Birmingham Cancer Center
Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
University of Alabama at Birmingham Cancer Center
Phase 2
Sacramento, California1 trial
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
UC Davis Comprehensive Cancer Center
Phase 1/2
Philadelphia, Pennsylvania1 trial
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University Hospital
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.